Search Results - "De Melo Gagliato, Debora"

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors by Jardim, Denis L, de Melo Gagliato, Débora, Giles, Francis J, Kurzrock, Razelle

“…Immune checkpoint inhibitors have unique toxicities and response kinetics compared with cytotoxic and gene-targeted anticancer agents. We investigated the…”
Get full text

Delays in Adjuvant Chemotherapy Among Breast Cancer Patients: An Unintended Consequence of Breast Surgery? by de Melo Gagliato, Debora, Chavez-MacGregor, Mariana

Get full text

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic by Jardim, Denis L F, Tang, Chad, Gagliato, Debora De Melo, Falchook, Gerald S, Hess, Kenneth, Janku, Filip, Fu, Siqing, Wheler, Jennifer J, Zinner, Ralph G, Naing, Aung, Tsimberidou, Apostolia M, Holla, Vijaykumar, Li, Marylin M, Roy-Chowdhuri, Sinchita, Luthra, Raja, Salgia, Ravi, Kurzrock, Razelle, Meric-Bernstam, Funda, Hong, David S

“…This study aimed to assess MET amplification among different cancers, association with clinical factors and genetic aberrations and targeted therapy response…”
Get full text

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge by de Melo Gagliato, Debora, C Buzaid, Antonio, Perez-Garcia, Jose Manuel, Llombart, Antonio, Cortes, Javier

“…Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors…”
Get full text

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker by Jardim, Denis L., Goodman, Aaron, de Melo Gagliato, Debora, Kurzrock, Razelle

“…Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed to neo-antigens and presented by major histocompatibility complex…”
Get full text

The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer by Chae, Young Kwang, Gagliato, Debora de Melo, Pai, Sachin Gopalkrishna, Carneiro, Benedito, Mohindra, Nisha, Giles, Francis Joseph, Ramakrishnan-Geethakumari, Praveen, Sohn, Joohyuk, Liu, Shuying, Chen, Huiqin, Ueno, Naoto, Hortobagyi, Gabriel, Gonzalez-Angulo, Ana Maria

“…EGFR and cMET cross-talk is involved in breast cancer (BC) progression and resistance to different targeted therapies, however little is known about the…”
Get full text

Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing by Roy-Chowdhuri, Sinchita, de Melo Gagliato, Debora, Routbort, Mark J., Patel, Keyur P., Singh, Rajesh R., Broaddus, Russell, Lazar, Alexander J., Sahin, Aysegul, Alvarez, Ricardo H., Moulder, Stacy, Wheler, Jennifer J., Janku, Filip, Gonzalez-Angulo, Ana M., Chavez-MacGregor, Mariana, Valero, Vicente, Ueno, Naoto T., Mills, Gordon, Mendelsohn, John, Yao, Hui, Aldape, Kenneth, Luthra, Rajyalakshmi, Meric-Bernstam, Funda

“…Objectives The advent of next-generation sequencing (NGS) platforms in the realm of clinical molecular diagnostics provides multigene mutational profiling…”
Get full text

Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges by de Melo Gagliato, Debora, Buzaid, Antonio C., Perez-Garcia, Jose, Cortes, Javier

“…Immunotherapy is currently approved for a subset of patients diagnosed with advanced triple negative breast cancer (TNBC), based on the phase III randomized…”
Get full text

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer by de Melo Gagliato, Debora, Jardim, Denis Leonardo Fontes, Marchesi, Mario Sergio Pereira, Hortobagyi, Gabriel N

“…Breast Cancer (BC) is a highly prevalent disease. A woman living in the United States has a 12.3% lifetime risk of being diagnosed with breast cancer [1]. It…”
Get full text

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology by Jardim, Denis L., de Melo Gagliato, Débora, Kurzrock, Razelle

“…Immunotherapies are becoming increasingly important in the treatment armamentarium of a variety of malignancies. Immune checkpoint inhibitors are the most…”
Get full text

Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer by DE MELO GAGLIATO, Debora, GONZALEZ-ANGULO, Ana M, XIUDONG LEI, THERIAULT, Richard L, GIORDANO, Sharon H, VALERO, Vicente, HORTOBAGYI, Gabriel N, CHAVEZ-MACGREGOR, Mariana

“…For patients with breast cancer (BC), the optimal time to initiation of adjuvant chemotherapy (TTC) after definitive surgery is unknown. We evaluated the…”
Get full text

Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice by de Melo Gagliato, Debora, Cortes, Javier, Curigliano, Giuseppe, Loi, Sherene, Denkert, Carsten, Perez-Garcia, Jose, Holgado, Esther

“…Breast Cancer (BC) can be classified using pathologic features, such as grade and tumor size. It can be categorized based on the gene expression profile, which…”
Get full text

Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2− advanced breast cancer: a Brazilian public health care system perspective by Rosa, Daniela Dornelles, Magliano, Carlos Alberto da Silva, Simon, Sergio D., Amorim, Gilberto, Reinert, Tomás, Landeiro, Luciana, Gagliato, Débora de Melo, Exman, Pedro, Argolo, Daniel, Guilgen, Gisah, Mano, Max, Testa, Laura, Liedke, Pedro, Barroso, Romualdo, Sasse, Mariana, Buehler, Anna Maria

“…Introduction: The MONALEESA-7 trial compared ribociclib plus endocrine therapy (ET) with placebo as first-line treatment of advanced luminal/HER2-negative…”
Get full text

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds by Jardim, Denis L., De Melo Gagliato, Débora, Nikanjam, Mina, Barkauskas, Donald A., Kurzrock, Razelle

“…Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of…”
Get full text

Clinical outcomes based on multigene profiling in metastatic breast cancer patients by Basho, Reva K, de Melo Gagliato, Debora, Ueno, Naoto T, Wathoo, Chetna, Chen, Huiqin, Shariati, Maryam, Wei, Caimiao, Alvarez, Ricardo H, Moulder, Stacy L, Sahin, Aysegul A, Roy-Chowdhuri, Sinchita, Chavez-MacGregor, Mariana, Litton, Jennifer K, Valero, Vincent, Luthra, Raja, Zeng, Jia, Shaw, Kenna R, Mendelsohn, John, Mills, Gordon B, Tripathy, Debu, Meric-Bernstam, Funda

“…Identifying the clinical impact of recurrent mutations can help define their role in cancer. Here, we identify frequent hotspot mutations in metastatic breast…”
Get full text

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic by Tang, Chad, Hess, Kenneth, Jardim, Denis Leonardo F, Gagliato, Debora De Melo, Tsimberidou, Apostolia M, Falchook, Gerald, Fu, Siqing, Janku, Filip, Naing, Aung, Piha-Paul, Sarina, Subbiah, Vivek, Wheler, Jennifer, Zinner, Ralph G, Kurzrock, Razelle, Ellis, Lee M, Meric-Berstam, Funda, Hong, David S

“…We hypothesized that chemotherapy synergizes with VEGF/VEGFR (VEGF/R) inhibitors in patients with advanced solid malignancies. Patients treated on phase I…”
Get full text

Biological therapies in breast cancer: Common toxicities and management strategies by Barroso-Sousa, Romualdo, Santana, Iuri A, Testa, Laura, de Melo Gagliato, Débora, Mano, Max S

“…Abstract In recent years, a number of new molecules – commonly known as biological therapies – have been approved or are in late stages of regulatory…”
Get full text

Noninvasive cancer biomarkers in solid malignancies: circulating tumor DNA-clinical utility, current limitations and future perspectives by de Melo Gagliato, Debora, Fontes Jardim, Denis L

Get full text

Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit by de Melo Gagliato, Debora, Jardim, Denis L. Fontes, Falchook, Gerald, Tang, Chad, Zinner, Ralph, Wheler, Jennifer J, Janku, Filip, Subbiah, Vivek, Piha-Paul, Sarina A, Fu, Siqing, Hess, Kenneth, Roy-Chowdhuri, Sinchita, Moulder, Stacy, Gonzalez-Angulo, Ana M, Meric-Bernstam, Funda, Hong, David S

“…Micro-Abstract MET aberrations were associated with adverse tumor pathologic features, such as high grade and hormone receptor negativity in a cohort of breast…”
Get full text

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit by Jardim, Denis L Fontes, de Melo Gagliato, Debora, Falchook, Gerald S, Janku, Filip, Zinner, Ralph, Wheler, Jennifer J, Subbiah, Vivek, Piha-Paul, Sarina A, Fu, Siqing, Murphy, Mariela Blum, Ajani, Jaffer, Tang, Chad, Hess, Kenneth, Hamilton, Stanley R, Roy-Chowdhuri, Sinchita, Kurzrock, Razelle, Meric-Bernstam, Funda, Hong, David S

“…We sought to investigate the demographics and tumor-associated features in patients with gastroesophageal (GE) malignancies referred to our Phase I Program who…”
Get full text